ArticleESC heart failure2021
Late gadolinium enhancement characteristics in giant cell myocarditis.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Giant cell myocarditis: from immune pathogenesis to contemporary management.Heart failure reviews · 2026Review
- Diagnostic challenges in isolated cardiac sarcoidosis.ESC heart failure · 2026Review
- Impact of Early Diagnosis and Immunosuppressive Therapy on Giant Cell Myocarditis Outcomes: A Review.Life (Basel, Switzerland) · 2026Review
- Giant cell myocarditis in a middle-aged male: features in CMR.The international journal of cardiovascular imaging · 2025Article
- Early Recognition of Giant Cell Myocarditis in a Patient With Fascicular Ventricular Tachycardia.JACC. Case reports · 2025Article
- Cardiovascular magnetic resonance imaging and endomyocardial biopsy in giant cell myocarditis: a case report on diagnostic challenges and future perspectives.European heart journal. Case reports · 2025Article
- Complete remission of giant cell myocarditis by prednisolone monotherapy: A case with mild inflammation demonstrated by mismatch between T2-high intensity areas and late gadolinium enhancement.Journal of cardiology cases · 2024Article
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024Review
- Sarcoid heart disease and imaging.Heart rhythm O2 · 2024Review
- Cardiovascular magnetic resonance (CMR) and positron emission tomography (PET) imaging in the diagnosis and follow-up of patients with acute myocarditis and chronic inflammatory cardiomyopathy : A review paper with practical recommendations on behalf of the European Society of Cardiovascular Radiology (ESCR).The international journal of cardiovascular imaging · 2023Review
- Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.European heart journal · 2023Article
- Cardiac magnetic resonance in giant cell myocarditis: a matched comparison with cardiac sarcoidosis.European heart journal. Cardiovascular Imaging · 2023Article
- Giant cell myocarditis after first dose of BNT162b2 - a case report.European journal of heart failure · 2022Article
- Cardiovascular Magnetic Resonance in Myocarditis.Diagnostics (Basel, Switzerland) · 2022Review
- Role of Cardiovascular Magnetic Resonance to Assess Cardiovascular Inflammation.Frontiers in cardiovascular medicine · 2022Review
- Cardiac involvement in patients 1 year after recovery from moderate and severe COVID-19 infections.Frontiers in cardiovascular medicine · 2022Article
- Late gadolinium enhancement characteristics in giant cell myocarditis.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to demonstrate the characteristics of late gadolinium enhancement (LGE) assessed by cardiovascular magnetic resonance (CMR) imaging in patients with giant cell myocarditis (GCM). METHODS AND
resultsSix patients histologically diagnosed with GCM were retrospectively recruited in this study. All of them underwent CMR during hospitalization. The distribution and extent of LGE were assessed on both ventricles, and the AHA-17 segment model was used for left ventricular (LV) analysis. Nine case reports with CMR in GCM were reviewed and summarized to investigate the features of LGE further. LGE was detected on both ventricular walls in all subjects. For a detailed analysis of LGE in the LV, the extent ranged from 21.6% to 56%. Among 70 segments (68.6%) involved by LGE, the subendocardial LGE was the most common pattern (46/102, including 24 segments located in the right-sided septum), followed by the subepicardial pattern (23/102). The right-sided septum, the subepicardial anterior wall, and the subendocardial right ventricular (RV) wall were observed in all subjects. To summarize the results of the present study with these case reports, the three most common patterns of LGE are the right-sided septum (73%), the subepicardial anterior wall (60%), and the subendocardial RV wall (53%).
conclusionsExtensive LGE seems to be common in GCM, affecting both LV and RV walls. Apart from subepicardial LGE, subendocardial LGE, which was used to be implicated in ischaemic disease, was frequently presented in GCM. The right-sided subendocardial septum, the subepicardial anterior wall, and the subendocardial RV wall might be the vulnerable areas of LGE in GCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.